Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden (Q50575997)

15 March 2018

title

Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden (English)

1 reference

15 March 2018

0 references

1 reference

1 reference

peginterferon alfa-2b

1 reference

1 reference

Lars Bernfort

1 reference

15 March 2018

Karin Sennfält

series ordinal

1 reference

15 March 2018

Olle Reichard

series ordinal

1 reference

15 March 2018

publication date

1 January 2006

1 reference

15 March 2018

published in

Infectious Diseases

1 reference

15 March 2018

volume

1 reference

15 March 2018

issue

6-7

1 reference

15 March 2018

page(s)

497-505

1 reference

15 March 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Is severe liver disease a common outcome for people with chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

Comparing the public health burden of chronic hepatitis C and HIV infection in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500532803

10.1080/00365540500532803

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018